Parkinson’s Disease

Parkinson’s disease patients suffer from many symptoms impacting their everyday lives. Motor impairment may be most visible, but drug development teams are increasingly looking to address non-motor aspects based on patient feedback.

Cogstate can help your team gather quality data via sensitive and reliable digital cognitive testing, as well as supporting endpoint data quality programs for the full range of PD symptoms including motor function, quality of life, depression, suicidality, symptom severity, and sleep.


Improve Strategic Study Design

The Cogstate team of cognitive scientists and statisticians have the expertise to advise your team on vital study considerations, help you answer key drug development questions, and reduce risk and uncertainty in your trial.

With access to thousands of cognitive data profiles—and from decades supporting drug development work—Cogstate can advise your team on endpoint selection, powering decisions, and interpretation of study results supportive of product efficacy, safety, and differentiating claims.

Implement Robust Endpoint Data Quality Programs

From helping you establish rater qualification criteria, to tailored certification pathways that credit the experience of expert raters, to central monitoring programs that target clinician reviews where they’re needed most, Cogstate supports all aspects of rater training and endpoint data quality programs. Studies also benefit from our global network of 180 highly trained expert clinicians who provide assessment support in 40+ languages.

Cogstate has expertise collaborating with the Movement Disorder Society (MDS) to coordinate training on commonly used MDS scales including the MDS-UPDRS and UDysRS; we have produced training materials on commonly used scales in PD studies (e.g., PDQ-39, PDSS-2, etc).

More on Rater Services

Leverage Sensitive and Reliable Digital Tests 

Cogstate digital assessments provide rapid and reliable measurement of distinct domains affected by PD and enable you to capture a complete and nuanced picture of a subject’s cognitive state.

Cogstate tests are culture- and education-neutral and designed for repeated administration with minimal practice or learning effects, making them ideal for use in global clinical trials. Normative data is available for both clinical samples and healthy controls. Study teams can choose the tests that best suit their research questions. Each test has been used in drug trials.

More on Digital Assessments

Sample Parkinson’s Disease Battery

The tests included are a sample battery based on domains commonly impacted by PD. Final battery recommendations vary based on study needs.

Cogstate Tests:International Shopping List Tests
Detection Test
Identification Test
One Card Learning Test
One Back Test
Two Back Test
Groton Maze Learning Test
Length:Between 5-40 minutes
(depending on the number of tests included in the battery)
Data Processing and Scoring:Automated
Application:Phase I-IV
Culture and Language Neutral:Yes

Wearable Sensors for a Complete Picture of Patient Functioning

Cogstate works with our partners at Clario to  deliver a complete wearable precision motion sensor solution that provides meaningful and functional insights for sponsors and patients through the capture of digital biomarkers. When integrated with Cogstate’s clinical outcome assessments of cognition, Clario’s data capture solutions for cardiac safety, eCOA, digital patient, imaging, or respiratory, digital biomarkers provide a holistic story of how a disease and therapy impacts patient function. 

How can we help you optimize the measurement of brain health?

Contact Our Team